当前蛋白身份:P97287 重新检索
本组结构的主要差异维度
构建体不同 突变/修饰不同 组装状态不同 配体/离子不同 实验方法不同 实验环境不同 结构质量指标不同

差异标签只比较当前检索结果;所有PDB和assembly原始记录仍分别保留。

相关结构差异明细

一行代表一个 PDB 条目中的一个 biological assembly;同一蛋白的多个单体会分别列出。

PDB 条目 Assembly / 聚集状态 构建体 突变与修饰 配体、离子与非聚合物 实验方法 实验环境 结构质量
1WSX Solution structure of MCL-1 提交 2004-11-12 Assembly 1 蛋白单体 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 152–308(157 aa) 片段:residues 152-308
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 6.7;298 K;离子强度(mmCIF原始值)120mM;压力 ambient
NMR样品组成 1mM U-15N Mcl-1 | 50mM Sodium Phoshate; 70mM Sodium Chloride; 0.04% Sodium Azide; 95% H2O, 5% D2O
NMR样品组成 1mM U-13C,15N Mcl-1 | 50mM Sodium Phoshate; 70mM Sodium Chloride; 0.04% Sodium Azide; 95% H2O, 5% D2O
分辨率未提供
2JM6 Solution structure of MCL-1 complexed with NOXAB 提交 2006-10-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 B 152–308(157 aa) 片段:residues 152-308
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 6.7;298 K;离子强度(mmCIF原始值)120;压力 ambient
NMR样品组成 0.5 mM [U-99% 13C, U-99% 15N] MCL_1, 0.5 mM NOXAB, 95% H2O, 5% D2O | 95% H2O/5% D2O
NMR样品组成 0.5 mM MCL-1, 0.5 mM [U-100% 13C, U-100% 15N] NOXAB, 95% H2O, 5% D2O | 95% H2O/5% D2O
NMR样品组成 0.5 mM [U-15N] MCL-1, 0.5 mM NOXAB, 95% H2O, 5% D2O | 95% H2O/5% D2O
分辨率未提供
2NL9 Crystal structure of the Mcl-1:Bim BH3 complex 提交 2006-10-19 Assembly 1 信息不足 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 152–189(38 aa) 片段:residues 171-208 and residues 209-327
非标准单体:是(mmCIF未提供具体位点) ZN ZINC ION × 7 CL CHLORIDE ION × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.75;298 K;0.2M zinc acetate, 0.2M imidazole, 2mM TCEP, pH 5.75, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 1.55 Å R-free 0.203
2NL9 Crystal structure of the Mcl-1:Bim BH3 complex 提交 2006-10-19 Assembly 2 信息不足 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 A 152–189(38 aa) 片段:residues 171-208 and residues 209-327
非标准单体:是(mmCIF未提供具体位点) ZN ZINC ION × 28 CL CHLORIDE ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.75;298 K;0.2M zinc acetate, 0.2M imidazole, 2mM TCEP, pH 5.75, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 1.55 Å R-free 0.203
2NL9 Crystal structure of the Mcl-1:Bim BH3 complex 提交 2006-10-19 Assembly 3 信息不足 异源复合物;蛋白 × 8 PDB 声明:octameric(8) 与蛋白数一致
链 A 152–189(38 aa) 片段:residues 171-208 and residues 209-327
非标准单体:是(mmCIF未提供具体位点) ZN ZINC ION × 28 CL CHLORIDE ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.75;298 K;0.2M zinc acetate, 0.2M imidazole, 2mM TCEP, pH 5.75, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 1.55 Å R-free 0.203
2NLA Crystal structure of the Mcl-1:mNoxaB BH3 complex 提交 2006-10-19 Assembly 1 信息不足 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 152–189(38 aa) 片段:residues 171-208 and residues 209-327
未记录 未记录非水小分子 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;12% PEG 4K, 4% isopropanol, 5% dioxane, 0.1M tris-HCl, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.80 Å R-free 0.291
2ROC Solution structure of Mcl-1 Complexed with Puma 提交 2008-03-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 152–308(157 aa) 片段:residues 152-308
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 6.7;298 K;离子强度(mmCIF原始值)120 mM;压力 ambient
NMR样品组成 0.5mM [U-100% 13C; U-100% 15N] Mcl-1; 0.5mM Puma; 95% H2O/5% D2O | 95% H2O/5% D2O
NMR样品组成 0.5mM Mcl-1; 0.5mM [U-100% 13C; U-100% 15N] Puma; 95% H2O/5% D2O | 95% H2O/5% D2O
分辨率未提供
2ROD Solution Structure of MCL-1 Complexed with NoxaA 提交 2008-03-17 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 152–308(157 aa) 片段:residues 152-308
未记录 未记录非水小分子 SOLUTION NMR
NMR测量条件 pH 6.7;298 K;离子强度(mmCIF原始值)120 mM;压力 ambient
NMR样品组成 0.5mM [U-100% 13C; U-100% 15N] Mcl-1; 0.5mM NoxaA; 95% H2O/5% D2O | 95% H2O/5% D2O
NMR样品组成 0.5mM Mcl-1; 0.5mM [U-100% 13C; U-100% 15N] NoxaA; 95% H2O/5% D2O | 95% H2O/5% D2O
分辨率未提供
3D7V Crystal structure of Mcl-1 in complex with an Mcl-1 selective BH3 ligand 提交 2008-05-22 Assembly 1 信息不足 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 152–189(38 aa) 片段:Bcl-2 like domain, Myeloid Cell Leukemia 1
未记录 ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.75;298 K;0.2M Zinc Acetate, 0.2M Imidazole, pH 5.75, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.03 Å R-free 0.241
3IO9 BimL12Y in complex with Mcl-1 提交 2009-08-14 Assembly 1 信息不足 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 152–189(38 aa) 片段:Fusion protein of mouse Mcl-1 residues 152-189 and human Mcl-1 residues 209-327
未记录 ZN ZINC ION × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 5.75;298 K;0.15M zinc acetate, 0.15 M imidizole, pH 5.75, VAPOR DIFFUSION, HANGING DROP, temperature 298K
分辨率 2.40 Å R-free 0.251
4BPI Mcl-1 bound to alpha beta Puma BH3 peptide 2 提交 2013-05-27 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 152–189(38 aa) 片段:FUSION PROTEIN OF MOUSE MCL-1, RESIDUES 152-189 AND HUMAN MCL-1, RESIDUES 209-327
未记录 CD CADMIUM ION × 10 X-RAY DIFFRACTION
X-ray结晶条件 pH 7.5;0.1M HEPES, PH7.5 1M SODIUM ACETATE, 0.05M CADMIUM SULPHATE
分辨率 1.98 Å R-free 0.243
4BPJ Mcl-1 bound to alpha beta Puma BH3 peptide 3 提交 2013-05-27 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 152–308(157 aa) 片段:FUSION PROTEIN OF MOUSE MCL-1, RESIDUES 152-189 AND HUMAN MCL-1 RESIDUES, 209-327
未记录 ZN ZINC ION × 10 CL CHLORIDE ION × 8 X-RAY DIFFRACTION
X-ray结晶条件 pH 7;0.2M IMADAZOLE, PH7.0 0.2M ZINC ACETATE
分辨率 1.60 Å R-free 0.230
4G35 Mcl-1 in complex with a biphenyl cross-linked Noxa peptide. 提交 2012-07-13 Assembly 1 蛋白异源复合物 异源复合物;蛋白 × 2 PDB 声明:dimeric(2) 与蛋白数一致
链 A 152–308(157 aa) 片段:residues 152-308
未记录 4BP 4,4'-bis(bromomethyl)biphenyl × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, HANGING DROP;pH 8.5;293 K;15% Peg 8000, 225 mM CaCl2, 2% Ethylene Glycol,50 mM Epps (pH 8.5), VAPOR DIFFUSION, HANGING DROP, temperature 293K
分辨率 2.00 Å R-free 0.239
5MES MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 29 提交 2016-11-16 Assembly 1 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 153–221(69 aa)
未记录 7LT (5~{R},13~{S},17~{S})-5-[[4-chloranyl-3-(2-phenylethyl)phenyl]methyl]-13-[(4-chlorophenyl)methyl]-8-methyl-1,4,8,12,16-pentazatricyclo[15.8.1.0^{20,25}]hexacosa-20(25),21,23-triene-3,7,15,26-tetrone × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;PEG 8K 10%w/v, PEG 1500 10%w/v
分辨率 2.24 Å R-free 0.230
5MEV MCL1 FAB COMPLEX IN COMPLEX WITH COMPOUND 21 提交 2016-11-16 Assembly 1 信息不足 异源复合物;蛋白 × 3 PDB 声明:trimeric(3) 与蛋白数一致
链 A 153–221(69 aa)
未记录 7LW (5~{R},13~{S},17~{S})-5-[(3,4-dichlorophenyl)methyl]-8-methyl-13-[(4-methylsulfonylphenyl)methyl]-1,4,8,12,16-pentazatricyclo[15.8.1.0^{20,25}]hexacosa-20,22,24-triene-3,7,15,26-tetrone × 1 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;293 K;PEG 8K 10%w/v, PEG 1500 10%w/v
分辨率 2.94 Å R-free 0.302
5VX2 Mcl-1 in complex with Bim-h3Pc-RT 提交 2017-05-23 Assembly 1 信息不足 异源复合物;蛋白 × 4 PDB 声明:tetrameric(4) 与蛋白数一致
链 A 152–189(38 aa) 片段:UNP P97287 residues 152-189, UNP Q07820 residues 209-327
链 C 152–189(38 aa) 片段:UNP P97287 residues 152-189, UNP Q07820 residues 209-327
未记录 EDO 1,2-ETHANEDIOL × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION;281 K;20 % PEG 3000, 100 mM trisodium citrate buffered with citric acid pH 5.5
分辨率 1.85 Å R-free 0.210
6DM8 Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) inhibitors 提交 2018-06-04 Assembly 1 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 A 154–302(149 aa)
未记录 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;291 K;PEG6000, Bicine
分辨率 2.70 Å R-free 0.288
6DM8 Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) inhibitors 提交 2018-06-04 Assembly 2 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 B 154–302(149 aa)
未记录 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;291 K;PEG6000, Bicine
分辨率 2.70 Å R-free 0.288
6DM8 Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) inhibitors 提交 2018-06-04 Assembly 3 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 C 154–302(149 aa)
未记录 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;291 K;PEG6000, Bicine
分辨率 2.70 Å R-free 0.288
6DM8 Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) inhibitors 提交 2018-06-04 Assembly 4 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 D 154–302(149 aa)
未记录 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;291 K;PEG6000, Bicine
分辨率 2.70 Å R-free 0.288
6DM8 Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) inhibitors 提交 2018-06-04 Assembly 5 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 E 154–302(149 aa)
未记录 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 2 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;291 K;PEG6000, Bicine
分辨率 2.70 Å R-free 0.288
6DM8 Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) inhibitors 提交 2018-06-04 Assembly 6 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 F 154–302(149 aa)
未记录 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;291 K;PEG6000, Bicine
分辨率 2.70 Å R-free 0.288
6DM8 Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) inhibitors 提交 2018-06-04 Assembly 7 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 G 154–302(149 aa)
未记录 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 3 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;291 K;PEG6000, Bicine
分辨率 2.70 Å R-free 0.288
6DM8 Understanding the Species Selectivity of Myeloid cell leukemia-1 (Mcl-1) inhibitors 提交 2018-06-04 Assembly 8 信息不足 单体;蛋白 × 1 PDB 声明:monomeric(1) 与蛋白数一致
链 H 154–302(149 aa)
未记录 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 4 X-RAY DIFFRACTION
X-ray结晶条件 VAPOR DIFFUSION, SITTING DROP;pH 8.5;291 K;PEG6000, Bicine
分辨率 2.70 Å R-free 0.288